Cardiac RadiothErapy for VEntricular Tachycardia II
Cardiac RadiothErapy for VEntricular Tachycardia II - a Prospective Observational Cohort Study
Universitaire Ziekenhuizen KU Leuven
50 participants
Jan 1, 2025
OBSERVATIONAL
Conditions
Summary
Steoreotactic therapy radioablation has become a standard of care option for patients with therapy-refractory ventricular tachycardia, yet long-term outcome is lacking. The objective of this study is to evaluate the long-term outcomes, both efficacy and safety, after STAR in patients with therapy-refractory ventricular tachycardia.
Eligibility
Inclusion Criteria2
- Eligible for STAR for therapy-refractory VT based on a multidisciplinary discussion
- Ability to give a written informed consent and willingness to return for follow-up
Exclusion Criteria2
- Contra-indications for STAR, including pregnancy or breastfeeding, previous radiotherapy with cardiac involvement, life-expectancy < 6 months in the absence of VT
- Any condition that is deemed a contraindication in the judgment of the investigators
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Single dose of 25 Gy up to 32.5 Gy on the myocardium in patients with therapy-refractory ventricular tachycardia
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06744530